Congress Just Quietly Handed Drug Companies a Dangerous Victory -

Christmas came early for the pharmaceutical industry when Congress passed the 21st Century Cures Act. Though lauded by liberals for funding medical research, its real impact will be elsewhere, including encouraging FDA to approve cancer drugs and other “cures” that don’t work.

Trump’s Rumored FDA Candidate Strikes Nerve -

December 8, 2016 – Against all expert opinion, Jim O’Neill, “a snake oil salesman” with no medical background, is rumored to head the Food and Drug Administration (FDA) in 2017

To fund projects like the Cancer Moonshot, Congress had to strip away some of the FDA’s most important regulatory powers -

The 21st Century Cures Act passed in the House, but comes with a lot of regulatory compromise and threats to patient safety. Most notably, Senator Warren and Senator Sanders oppose the bill along with NCHR President Diana Zuckerman due to patient safety concerns and breaks for Big Pharma. “It really is a David and Goliath issue of where the money is,” said Dr. Zuckerman.

FDA hearing on off-labels use of devices explores risks to patients -

Star Tribune, November 10, 2016 – CPTF President Diana Zuckerman said the Infuse Bone Graft is “contraindicated” for children. But the FDA’s 2015 warning didn’t ban the product in kids because some children have such significant bone defects or such rare bone disorders that they would be willing to accept the risks.